Clinical Trial Update: A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II [Phase 3]

View source ↗

Summary

A Phase 3 study of SEL-212 in patients with chronic gout refractory to conventional therapy has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• SEL-212

Snippet

Sponsor: Swedish Orphan Biovitrum | Conditions: Chronic Gout | Phase 3 | Status: COMPLETED | Results posted: 2025-12-03